ProCE Banner Activity

Ruxolitinib + 5-Azacitidine in Myelodysplastic/Myeloproliferative Neoplasms

Slideset Download
Conference Coverage
Reduced splenomegaly observed with the combination, and patients with JAK2 mutations achieved higher response rates vs those without.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen